Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents—a multicenter historical prospective study
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Hematology"
DOI: 10.1007/s00277-019-03719-6
Abstract: Patients with acute myeloid leukemia (AML) who progress after exposure to hypomethylating agents (HMA) have a dismal prognosis. We hypothesized that the addition of venetoclax, a BCL-2 inhibitor, to AML patients who previously failed HMA… read more here.
Keywords: patients acute; myeloid leukemia; venetoclax patients; hypomethylating agents ... See more keywords
Addition of Venetoclax to Patients with Acute Myeloid Leukemia Relapsing after Treatment with Hypomethylating Agents. Multicenter Historical Prospective Study
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-113596
Abstract: Introduction - Patients who experience relapse of acute myeloid leukemia or progress after exposure to hypomethylating agents (HMA's) have a dismal prognosis. Specifically, elderly patients lack effective salvage therapies in this setting. Venetoclax is a… read more here.
Keywords: myeloid leukemia; venetoclax patients; addition venetoclax; acute myeloid ... See more keywords
A Multicenter Analysis of the Outcomes with Venetoclax in Patients with Relapsed Mantle Cell Lymphoma.
Sign Up to like & getrecommendations! Published in 2023 at "Blood advances"
DOI: 10.1182/bloodadvances.2022008916
Abstract: To report the activity of venetoclax in patients with relapsed mantle cell lymphoma (MCL), we identified 81 patients treated with venetoclax monotherapy (n=50, 62%) or in combination with a BTK inhibitor (n=16, 20%), an anti-CD20… read more here.
Keywords: venetoclax patients; relapsed mantle; risk; analysis ... See more keywords